Plain-English translation of NCT06153251 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which is made from your own immune cells that have been engineered in a laboratory to fight multiple myeloma. The medication is designed to recognize and attack cancer cells that have the specific markers BCMA and GPRC5D on their surface. Researchers want to find the right dose and see how well this treatment works for people whose myeloma has come back or stopped responding to standard therapies.
Multiple myeloma can become resistant to standard treatments, leaving patients with limited options. This medication offers a different approach by harnessing the body's own immune system to target the cancer, potentially helping people who have exhausted other treatment choices.
You likely qualify if…
You likely don't qualify if…
Researchers will first draw blood from you and send your immune cells to a laboratory, where they will be engineered to recognize myeloma cancer cells. After a period of preparation, you will receive the medication back as an infusion. The study will monitor you closely with blood tests, scans, and office visits to see how your body responds and whether the treatment helps control your cancer. The exact schedule and duration will depend on which group you are placed in and how you respond.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States